This insane video shows a car passing under a tree seconds before it came crashing to the ground
This insane video shows a car passing under a tree seconds before it came crashing to the ground
(Bloomberg) -- U.S. support for a proposal to waive intellectual-property protections for Covid-19 vaccines might be good news for the global inoculation campaign, but it’s an unwelcome turn for firms whose share prices have been buoyed by profits from coronavirus shots.Pfizer Inc., BioNTech SE, Novavax Inc. and CureVac NV declined Thursday in U.S. premarket trading. Shanghai Fosun Pharmaceutical Group Co., which has the rights to develop and market BioNTech’s shot in China, plunged 14% in Hong Kong, the most ever.With many countries struggling with a resurgence of the virus, U.S. Trade Representative Katherine Tai said Wednesday the Biden administration will take part in negotiations for the text of a waiver of the rights at the World Trade Organization. The European Union said Thursday it was willing to participate.CanSino Biologics Inc., which makes one of China’s domestic vaccines, tanked 15%. Walvax Biotechnology Co. dropped 11% and Chongqing Zhifei Biological Products Co. fell 8.7%, dragging the CSI 300 Index’s healthcare gauge more than 5% lower.In Japan, JCR Pharmaceuticals Co., a local partner for AstraZeneca Plc’s vaccine, slid 1.4% even as positive news around inoculations in western economies helped boost the benchmark Topix index 1.5% higher.Vaccines have been a big business for the firms that make them, with Pfizer, BioNTech’s partner outside of China, raising its forecast for 2021 vaccine sales to $26 billion just this week. Pfizer slipped 3.4% in premarket trading, while BioNTech slumped 7.3%, Novavax lost 2.8%, Curevac slipped 4.9% and Moderna Inc. fell 1.7%. Shares of many of the U.S.-listed companies had fallen late in Wednesday’s regular trading session after Tai’s comments.The U.S. move “probably isn’t great news for the vaccine manufacturers who will now face generic copies of their vaccine, but as the mutation of the virus has shown, continued research and innovation will be needed and that should provide those companies with future earnings from newer vaccines so I would expect the impact to be short-lived and possibly limited,” said Olivier d’Assier, head of APAC applied research at Qontigo GmbH.The International Federation of Pharmaceutical Manufacturers & Associations condemned the move as “disappointing.”“A waiver is the simple but the wrong answer to what is a complex problem,” the group said in a statement. “Waiving patents of Covid-19 vaccines will not increase production nor provide practical solutions needed to battle this global health crisis.”Umer Raffat, a senior managing director at Evercore ISI who specializes in the pharmaceutical industry, urged caution on the news, noting U.S. support didn’t mean it was a “100% done deal” as other countries are also opposed. It “remains to be seen if U.S. leadership’s position sways others,” Ruffat wrote in a note.(Updates with U.S. premarket trading in second paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The "Men's Personal Care Market Size, Share & Trends Analysis Report by Product (Skincare, Personal Grooming), by Distribution Channel (Hypermarket & Supermarket, Pharmacy & Drug Store, E-commerce), by Region, and Segment Forecasts, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
Former Rugby League player Jarryd Hayne is jailed for more than five years for the 2018 attack.
(Bloomberg) -- Nintendo Co.’s earnings beat estimates after hit games like Monster Hunter Rise propped up sales of the Switch, but the company warned that global chip shortages may disrupt production of its marquee device.It forecast 500 billion yen in operating profit this year, although Nintendo, like many Japanese companies, often begins the fiscal year with a conservative outlook so it has room to raise the figure later. The company is targeting sales of 25.5 million consoles in the current year ending March 2022. Internally, Nintendo’s management is shooting for production of between 28 and 29 million consoles, according to people familiar with the projections who asked not to be named disclosing company targets.Nintendo’s better-than-expected results suggest the Covid-era boom in gaming that turned Animal Crossing: New Horizons into a global online town hall has legs. The Kyoto-based studio reported operating income of 119.5 billion yen ($1.1 billion) for the March quarter, trouncing the average forecast of 68.3 billion yen. The company sold 28.8 million Switch units in the fiscal year ended March, surpassing the 26.5 million it projected.President Shuntaro Furukawa told reporters on Thursday that Nintendo wasn’t able to produce as many Switch devices as it had hoped due to component shortages. Recent demand has been higher than the company anticipated and the console hasn’t yet reached its peak, he added. Nintendo’s goal is now to surpass its official target of selling 190 million software units this year.The handheld-hybrid Switch maintained momentum in the face of newer gaming machines from Sony Group Corp. and Microsoft Corp., both of which have also suffered from chip shortages limiting production. Buoyed through most of 2020 by Animal Crossing’s runaway success, Nintendo’s signature device rode blockbuster titles including Capcom Co.’s latest Monster Hunter installment and Konami Holdings Corp.’s Momotaro Dentetsu during the most recent quarter.Nintendo’s own product lineup has been relatively quiet in recent months. Bloomberg News has reported that the company plans a big rollout of new titles alongside an upgraded version of the aging Switch -- with a faster Nvidia chip and a Samsung OLED display -- in the latter half of the year. The original console is now more than four years old and was joined by a more affordable Switch Lite variant in late 2019.What Bloomberg Intelligence SaysNintendo needs to drive software sales, live services and mobile games to support earnings growth beyond this fiscal year ending March, in our view, as the Switch platform enters the mature phase of its cycle. Switch hardware sales may peak in 2020 absent a reported but as yet unconfirmed Pro version, putting greater onus on software to drive profit.- Matthew Kanterman and Nathan Naidu, analystsClick here for the research.Read more: Nintendo Is Said to Target Record Year in Switch, Game SalesThe coronavirus outbreak was at first a brake and then an accelerant for Nintendo, choking its supply chain before triggering a demand surge with global lockdowns driving people to seek entertainment and escape. The company’s hardware sales improved by 37% and its software sales also rose 37% to 231 million units over the past fiscal year. It increased its proportion of sales coming from digital downloads to 43% from the previous 34%.Nintendo’s shares closed 1.7% lower Thursday before the results, taking losses this year to 6.4%.(Updates with comments from Nintendo president in fourth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The "Drug Patent Database Subscription: Drugs in Development" database has been added to ResearchAndMarkets.com's offering.
Major players in the insulin pens, syringes, pumps and injectors market are Novo Nordisk A/S (Denmark), Eli Lilly and Company, Medtronic plc (Ireland), Abbott, and Insulet Corporation (US).New York, May 06, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Insulin Pens, Syringes, Pumps And Injectors Global Market Report 2021: COVID 19 Implications And Growth to 2030" - https://www.reportlinker.com/p06067880/?utm_source=GNW The global insulin pens, syringes, pumps and injectors market is expected to grow from $18.83 billion in 2020 to $19.26 billion in 2021 at a compound annual growth rate (CAGR) of 2.3%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $25.12 billion in 2025 at a CAGR of 6.9%.The insulin pens, syringes, pumps, and injectors devices and equipment market consists of sales of insulin pens, syringes, pumps and injectors, and related services.Insulin pens are reusable pen-like tools used to inject desired the dose of insulin into the blood of a diabetic patient.Insulin helps to ensure that glucose levels in the patient’s blood are appropriate.Insulin syringes are the reusable devices used to inject insulin which is specifically made for self-administration.Insulin pumps and injectors are the devices that are used to deliver insulin continuously throughout the day to the diabetic patient and maintain blood glucose levels.Resistance towards self-injection by patients is restraining the insulin pens, syringes, pumps, and injectors market.The fear of injections causes anxiety in some patients thus causing them to avoid the use of insulin injections and being inconsistent in their insulin uptake.According to a report by, National Center for Biotechnology Information (NCBI) anxiety about and the fear of injection-associated pain has been estimated to affect approximately 30%–50% of patients, before the initiation of diabetes education interventions.The report also stated that close to 28% of patients were unwilling to initiate insulin therapy, if prescribed because they were not confident about handling the injections and the anticipated needle pain due to self-injection.This resistance to self-injection due to the fear of needles is hampering the growth of the market.In 2020, Medtronic, an Irish medical device company agreed to acquire Companion Medical, a manufacturer of InPen, for an undisclosed amount.The connected insulin pen helps users to manage their diabetes by tracking insulin doses and active insulin.This acquisition is an ideal strategic fit for Medtronic, to further simplify diabetes management and improve outcomes by optimizing dosing decisions for a large number of people using multiple daily injections (MDI). Companion Medical was founded by people with diabetes that fuels their drive to create insulin technologies that enable users to live their lives with diabetes solutions that make sense.An increase in the prevalence of diabetes globally is driving the growth of the insulin pens, syringes, pumps, and injectors market.The increase in the number of people suffering from obesity, unhealthy eating habits, physical inactivity, and the increasing geriatric population are some of the key factors which are leading to the increase in the global prevalence of diabetes.According to the US Centers for Disease Control and Prevention (CDC) in 2020, around 34.2 million people in the U.S. were suffering from diabetes. Also, according to the International Diabetes Federation, in 2019, globally approximately 463 million adults were living with diabetes; by 2045, this number would rise to 700 million, driving the insulin pens, syringes, pumps, and injectors market.The insulin pens, syringes, pumps, and injectors devices and equipment market is regulated by authorities such as the US FDA and European Medicines Agency.For instance, FDA’s Title 21 of the Code of Federal Regulations (CFR) provides guidelines for proper labeling of medical devices such as food, drugs, cosmetics, and other medical devices, the manufacturers of these devices must comply and adhere.FDA also provides strict label warnings prohibiting the sharing of insulin injectable medicines, to avoid infections in patients which are caused by the sharing of these insulin devices.Many companies are focusing on technological advancements in insulin delivery systems to deliver insulin effectively and safely.For instance, in June 2018, the US Food and Drug Administration approved MiniMed 670G hybrid closed looped system for curing diabetic individuals aged between 7-13 years of age.It is a diabetes management device that automatically monitors glucose and provides appropriate level insulin doses needed.It requires little or no input from the user.Similarly, in February 2019, the FDA also approved the Tandem Diabetes Care t: Slim X2 insulin pump.This pump uses interoperable technology that allows patients to customize their diabetes management devices according to their preferences.These devices contain automated insulin dosing systems, continuous glucose monitors, blood glucose meters, or other electronic devices.Read the full report: https://www.reportlinker.com/p06067880/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
The ASEAN region is seeing an increase in the demand for environmental services due to rapid population growth and urbanization, including waste and wastewater management, air pollution and climate change mitigation, according to the study by the ASEAN-Japan Centre, Promoting Services Trade in ASEAN: Trade in Environmental Services, published today. This is the third and last report in the three-paper series of social services under the second phase of the project on promoting services trade.
The cryptocurrency, which started as a joke in 2013, has rallied this week as internet users tried to push the value of the coin to $1 (£0.72).
(Bloomberg) -- Malaysia kept its benchmark interest rate at a record low Thursday as a fresh surge in coronavirus infections threatens to further delay an economic recovery.Bank Negara Malaysia held the overnight policy rate at 1.75% for a fifth straight meeting, a decision expected by all 21 economists in a Bloomberg survey.“Latest indicators point to continued improvements in economic activity in the first quarter and into April,” the central bank said in a statement Thursday. “While the recent re-imposition of containment measures in select locations will affect economic activity in the short term, the impact will be less severe as almost all economic sectors are allowed to operate.”Still, the statement noted that “the balance of risks to the growth outlook remains tilted to the downside,” due to uncertainty over the course of the pandemic and potential challenges for the country’s vaccine rollout.The decision comes as Malaysia suspended a domestic travel bubble and tightened movement curbs in Kuala Lumpur and in Selangor, its richest state, to contain a surge in infections that has left some hospitals low on ICU beds. Daily cases last week topped 3,000 for the first time since February.The ringgit was largely unchanged on the day at 4.1215 per dollar as of 4:38 p.m. Stocks erased earlier losses to trade little changed on the day.Recent GainsBank Negara Malaysia “spoke about how the current monetary policy stance remains appropriate, and how the virus curbs are less severe than before,” said Wellian Wiranto, an economist at Oversea-Chinese Banking Corp in Singapore. “From those alone, it does not look like a central bank that is laying the groundwork for any cut in the near term.”Further containment measures could undo recent strides the economy has made. The April manufacturing Purchasing Managers Index hit a record high, while March exports registered the strongest year-on-year growth in almost four years. Manufacturing sales rose at their fastest pace in nearly four years in March, while an index of industrial production showed its strongest gains in March since July 2013.What Bloomberg Economics Says...“Downside risks from the pandemic keep the door open for more rate cuts. Our base case, though, remains that BNM will leave its policy rate unchanged this year. This assumes global demand continues to recover, supporting commodity prices and market sentiment. The distribution of Covid-19 vaccines, albeit slow, should help to steadily lower new virus cases, allowing Malaysia’s social distancing measures to be pared back.”-- Tamara Mast Henderson, Asean economistConsumer prices surged to an almost three-year high in March, driven partly by a low base effect from last year, when tight movement restrictions pushed the country into deflation. The central bank expects headline inflation to average 2.5%-4% this year.“The fact that Bank Negara Malaysia (BNM) left its policy rate on hold at 1.75% today despite the worsening economic outlook means any further loosening is unlikely,” Alex Holmes, Asia economist at Capital Economics Ltd., wrote after the decision. “With the recovery set to be slow and fitful, we think BNM will leave interest rates at their current low until at least the end of 2022.”(Updates market levels in sixth paragraph, adds Bloomberg Economics comment in text box.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Everything you need to know ahead of tonight’s tie
Man Utd take a four goal advantage to Italy
Everything you need to know about tonight’s tie
Roma need a miracle comeback to progress to the final
All you need to know ahead of the squad announcement
Warren Gatland is set to announce his squad after months of deliberation
United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) ("UMC"), today reported unaudited net sales for the month of April 2021.
CNOOC Limited (the "Company", SEHK: 00883, NYSE: CEO, TSX: CNU) today announced that Liuhua 29-2 gas field has commenced production.
Dublin, May 06, 2021 (GLOBE NEWSWIRE) -- The "Testing, Inspection, and Certification Market by Service, End User (Retail, Agriculture, Oil and Gas, Construction, Chemicals, Machinery, Transportation, Automotive, Government, Marine, Healthcare), and Region - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. This report provides an in-depth analysis of the testing, inspection, and certification market in five major geographies and emphasizes on the current market trends, market size, market shares, recent developments, and forecast to 2027. The testing, inspection, and certification market is expected to reach $105.99 billion by 2027, at a CAGR of 2.4% during the forecast period, 2020-2027.The growth of this market is mainly attributed to the rise in the illicit trade of forged & pirated goods, strict regulatory standards imposed by governments, and the utilization of advanced technologies for new TIC processes. In addition, the rising awareness among consumers regarding product quality & safety and the growing significance of TIC services across various industry verticals are also expected to support the growth of the testing, inspection, and certification market in the coming years. However, concerns regarding the reliability of new service providers and an uncertain regulatory environment are expected to pose challenges to the growth of the testing, inspection, and certification market in the coming years.The study offers a comprehensive analysis of the TIC market with respect to services, end users, and geographies. The testing, inspection, and certification market is segmented by service (testing, inspection, and certification), end user (consumer goods and retail, agriculture and food, oil & gas, construction, chemicals, mining, machinery, transportation, automotive, power generation, government, marine, healthcare, financial institutions, and others). The study also evaluates industry competitors and analyzes the market at the country level.By service, the testing segment accounted for the largest in terms of market share in 2020. The largest share of this segment is primarily driven by the presence of different product standards across different regions, increasing product diversity, the rise of globalization, a surge in brand protection policies, and supportive government initiatives to improve the quality of various goods. However, the certification segment is slated to register the highest CAGR due to factors such as supportive government initiatives, the organizations' increasing need to enhance product value, increase safety, protect the environment, fulfill social responsibilities, and improve performance.By end user, the agriculture and food segment accounted for the largest in terms of market share in 2020. The largest share of this segment is mainly attributed to the increased need to ensure quality, closely monitor food items, and improve productivity and the growing demand for organic and processed foods. However, the healthcare sector is slated to grow at the fastest pace during the forecast period due to the growing favorability of the regulatory environment, the acceptance of the 'quality by design' (QbD) approach in pharmaceutical research and manufacture, rising demand for specialized testing services, and increase in the number of clinical trials.By geography, the testing, inspection, and certification market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the testing, inspection, and certification market in 2020. The largest share of this segment is mainly attributed to rapid economic development, the presence of major TIC players and several emerging start-ups in the region, highly developed IT infrastructure, stringent government regulations related to food testing, consumer product testing, and drone testing, and growing trade of consumer products. In addition, the growing demand for organic and processed foods and the organizations' increasing focus on meeting regulatory and compliance requirements are supporting the growth of the testing, inspection, and certification market in the region.Moreover, high investment opportunities owing to favorable government policies, growing consumer awareness about the importance of certification, testing, and inspection, an upsurge in food safety audits, growing investments by private and public players, and increasing demand for consumer electronics are expected to further support the growth of this regional market. The high adoption of advanced technologies and growing consumer awareness regarding quality are also expected to support the fastest growth of the Asia-Pacific market over the forecast period.The key players operating in the TIC market are SGS S.A. (Switzerland), Bureau Veritas S.A. (France), Intertek Group Plc. (U.K.), TUV Sud AG (Germany), Dekra SE (Germany), Eurofins Scientific SE (Luxembourg), TUV Rheinland AG Group (U.S.), Element Materials Technology Ltd. (U.K.), Lloyd's Register Group Limited (U.K.), APPLUS+ (Spain), AsureQuality (New Zealand), DNV GL (Norway), ALS Ltd. (Australia), Mistras Group (U.S.), and UL LLC (U.S.), among othersKey questions answered in the report Which are the high-growth market segments in terms of service, end user, and geography?What is the historical market size of the testing, inspection, and certification (TIC) market?What are the market forecasts and estimates for the period 2020-2027?What are the major drivers, restraints, opportunities, and trends in the testing, inspection, and certification market?Who are the major players in the testing, inspection, and certification market, and what shares of the market do they hold?How is the competitive landscape?What are the recent developments in the testing, inspection, and certification market?What are the various strategies adopted by the major players in the testing, inspection, and certification market?What are the geographical trends and high-growth countries?Who are the local emerging players in the testing, inspection, and certification market, and how do they compete with the other players? Key Topics Covered: 1. Introduction 1.1. Market Definition 1.2. Currency and Limitations 1.2.1. Currency 1.2.2. Limitations 2. Research Methodology 2.1. Research Approach 2.2. Data Collection & Validation 2.2.1. Secondary Research 2.2.2. Primary Research 2.3. Market Assessment 2.3.1. Market Size Estimation 2.3.2. Bottom-Up Approach 2.3.3. Top-Down Approach 2.3.4. Growth Forecast 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Analysis, by Service 3.2. Market Analysis, by Industry Vertical 3.3. Market Analysis, by Geography 3.4. Competitive Analysis 4. Market Insights 4.1. Introduction 4.2. Market Dynamics 4.3. Drivers 4.3.1. Strict Regulatory Standards Imposed by Governments 4.3.2. Rise in Illicit Trade of Forged and Pirated Goods 4.3.3. Inclination Towards Outsourcing TIC Services 4.4. Restraints 4.4.1. Dynamic International Regulatory Standards Across Regions 4.5. Opportunities 4.5.1. Surge in Consumer Awareness Towards Food Safety 4.6. Challenges 4.6.1. Lack of Testing Facilities and Skilled Resources 4.7. Trends 4.7.1. Use of Simulation in Product Testing and Validation 4.8. Impact of Covid-19 on the Testing, Inspection, and Certification Market 4.8.1. Scenario A: Severe Impact 4.8.2. Scenario B: Moderate Recovery 4.8.3. Scenario C: Fast Recovery 4.9. Case Study: Testing, Inspection and Certification Market 4.9.1. Case Study-A 4.9.2. Case Study-B 4.9.3. Case Study-C 4.9.4. Case Study-D 4.9.5. Case Study-E 5. Testing Inspection and Certification Market, by Service 5.1. Introduction 5.2. Testing Services 5.3. Inspection Services 5.4. Certification Services 6. Testing, Inspection, and Certification Market by Industry Vertical 6.1. Introduction 6.2. Agriculture and Food 6.3. Consumer Goods and Retail 6.4. Construction 6.5. Machinery 6.6. Oil & Gas 6.7. Chemicals 6.8. Automotive 6.9. Mining 6.10. Transportation 6.11. Healthcare 6.12. Power Generation 6.13. Marine 6.14. Government 6.15. Financial Institutions 6.16. Others 7. Testing, Inspection, and Certification Market, by Geography 7.1. Introduction 7.2. Europe 7.2.1. Germany 7.2.2. U.K 7.2.3. France 7.2.4. Italy 7.2.5. Spain 7.2.6. Rest of Europe 7.3. Asia-Pacific 7.3.1. China 7.3.2. Japan 7.3.3. India 7.3.4. Rest of Asia-Pacific 7.4. North America 7.4.1. U.S 7.4.2. Canada 7.5. Middle East & Africa 7.6. Latin America 8. Competitive Landscape 8.1. Introduction 8.2. Key Growth Strategies 8.3. Competitive Benchmarking 8.4. Market Share Analysis 9. Company Profiles9.1. SGS S.A 9.2. Bureau Veritas S.A. 9.3. Intertek Group Plc 9.4. TUV SUD 9.5. Dekra SE 9.6. TUV Rheinland AG Group 9.7. Applus+ 9.8. Eurofins Scientific SE 9.9. British Standards Institution (BSI) Group 9.10. Lloyd's Register Group Limited 9.11. Mistras Group, Inc. 9.12. DNV GL 9.13. Element Materials Technology 9.14. ALS 9.15. UL LLC 10. Appendix 10.1. Questionnaire 10.2. Available Customization For more information about this report visit https://www.researchandmarkets.com/r/gwzu94 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
All you need to know ahead of the second leg